Table 1.
Patient characteristics and PsA‐related treatment during the 12 months prior to initiating IXE
| IXE (N = 496) | |
|---|---|
| Age, mean (SD), yr | 51.1 (9.8) |
| Male sex, n (%) | 246 (49.6) |
| Payer commercial, n (%) | 466 (94.0) |
| Deyo‐Charlson comorbidity score, mean (SD) | 0.7 (1.4) |
| Comorbid conditions, n (%) | |
| Psoriasis | 463 (93.4) |
| Hypertension | 231 (46.6%) |
| Hyperlipidemia | 178 (35.9) |
| Obesity | 157 (31.7) |
| Osteoarthritis | 117 (23.6) |
| Diabetes | 102 (20.6) |
| Sleep apnea | 95 (19.2) |
| Other autoimmune disorders | 28 (5.7) |
| Depression | 77 (15.5) |
| Anxiety | 76 (15.3) |
| Cardiovascular diseases | 48 (9.7) |
| Uveitis | 6 (1.2) |
| Ulcerative colitis | 4 (0.8) |
| Crohn’s disease | 3 (0.6) |
| Biologic‐ or tsDMARD‐experienced, a n (%) | 456 (91.9) |
| Number of different biologic or tsDMARDs used, mean (SD) | 1.4 (0.6) |
| Type of biologic or tsDMARDs used in the 12 months prior to initiating IXE, n (%) | |
| Secukinumab | 173 (34.9) |
| Adalimumab | 143 (28.8) |
| Ustekinumab | 106 (21.4) |
| Apremilast | 95 (19.2) |
| Etanercept | 58 (11.7) |
| Certolizumab | 22 (4.4) |
| Subcutaneous golimumab | 13 (2.6) |
| Infliximab | 11 (2.2) |
| Subcutaneous abatacept | 7 (1.4) |
| Intravenous abatacept | 5 (1.0) |
| Tofacitinib | 5 (1.0) |
| Intravenous golimumab | 1 (0.2) |
| Other PsA treatments used in the 12 months prior to initiating IXE, n (%) | |
| Corticosteroids (oral or injectable) | 293 (59.1) |
| Methotrexate | 117 (23.6) |
| Leflunomide | 23 (4.6) |
| Sulfasalazine | 20 (4.0) |
| Cyclosporine | 11 (2.2) |
| Azathioprine | 2 (0.4) |
Abbreviations: IXE, ixekizumab; PsA, psoriatic arthritis; tsDMARD, targeted synthetic disease‐modifying antirheumatic drug.
a
Certolizumab, secukinumab, etanercept, adalimumab, abatacept, infliximab, golimumab, ustekinumab, apremilast, or tofacitinib.